itolizumab   Click here for help

GtoPdb Ligand ID: 9421

Synonyms: Alzumab® | T1h
Approved drug Immunopharmacology Ligand
itolizumab is an approved drug (DCGI (India; 2013))
Compound class: Antibody
Comment: Itolizumab is a first in class humanized IgG1 monoclonal antibody targeting T cell CD6. It is being developed by Biocon Limited for its anti-inflammatory potential in autoimmune conditions.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Itolizumab has been licensed India since 2013 as a treatmant for chronic plaque psoriasis [2-4]. Itolizumab has also been evaluated in patients with rheumatoid arthritis [5].